[{"id":"38aa9c92-b86b-4c71-ac1f-a0585bd922fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05987696","created_at":"2023-08-14T15:10:11.648Z","updated_at":"2024-07-02T16:35:40.228Z","phase":"Phase 1","brief_title":"Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia","source_id_and_acronym":"NCT05987696","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive • CD33 expression","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive • CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • fludarabine IV • CD33/CLL1 dual CAR-NK cell • Super NK cell therapy"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 08/10/2023","start_date":" 08/10/2023","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2023-08-11"}]